Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 29, 2015 7:24 PM ET

Pharmaceuticals

Company Overview of Aclaris Therapeutics, Inc.

Company Overview

Aclaris Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing novel topical dermatological therapeutics. The company develops A-101, a topical therapy for the treatment of seborrheic keratosis (a skin tumor in man). It is also engaged in pursuing additional dermatological indications for its product, as well as evaluating other dermatologic assets in various stages of preclinical and clinical development; and the development of topical agents for the treatment and prevention of various medical and cosmetic indications. Aclaris Therapeutics, Inc. was founded in 2012 and is based in Malvern, Pennsylvania.

101 Lindenwood Drive

Suite 400

Malvern, PA 19355

United States

Founded in 2012

Phone:

484-321-5554

Key Executives for Aclaris Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 45
Chief Financial Officer
Chief Operating Officer
Chief Legal Officer
Vice President of Clinical Operations
Compensation as of Fiscal Year 2015.

Aclaris Therapeutics, Inc. Key Developments

Aclaris Therapeutics, Inc. Announces Statistically Significant Results from Phase 2 Clinical Trial of Its Lead Drug Candidate, A-101

Aclaris Therapeutics, Inc. announced statistically significant results from a Phase 2 clinical trial of its lead drug candidate, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face. SK is one of the most common types of skin tumors. Although the lesions are benign, many patients elect to have SK treated, either because the lesions have become irritated or because the patient feels they are cosmetically concerning. The double-blind, vehicle-controlled Phase 2 clinical trial was designed to evaluate the safety, tolerability and effectiveness of A-101 in removing targeted SK lesions on the face. The trial used a parallel-group design to compare two concentrations of A-101 and vehicle (placebo) in 120 subjects with SK lesions on the face. Results from the trial showed A-101 achieved statistical significance in clearing SK lesions in a dose-related fashion. A-101 was well tolerated at both concentrations studied. SK are among the most common skin tumors seen in middle-aged and older adults, affecting over 83 million people in the United States.i SK lesions have a waxy, scaly, slightly elevated appearance and often multiple growths are present. Currently, SK lesions are treated using modalities such as cryosurgery, electrosurgery, curettage, or surgical removal which may be painful and may often result in pigmentary changes and/or scarring at the treatment site.

Aclaris Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:00 PM

Aclaris Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:00 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Neal Walker, Chief Executive Officer, President and Director.

Aclaris Therapeutics Announces Positive Results from Phase 2B Clinical Trial of A-101 for the Removal of Seborrheic Keratosis

Aclaris Therapeutics, Inc. announced positive results from a Phase 2b clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK), one of the most common types of skin tumors. Though the lesions are benign, many patients elect to have SK treated, either because the lesions are irritated or are cosmetically concerning. The double-blind, vehicle-controlled Phase 2b clinical trial was designed to evaluate the safety, tolerability and efficacy of A-101 in removing multiple SK lesions on the trunk and extremities. The trial used a parallel-group design to compare two concentrations of A-101 and vehicle (placebo) in 172 subjects with SK lesions. Results from the study showed A-101 achieved statistical significance in clearing SK lesions in a dose-related fashion. A-101 was well tolerated at both concentrations studied. This positive outcome represents an important milestone for A-101 and further demonstrates its potential as a non-invasive treatment for SK, a condition for which there are currently no FDA-approved therapies. These study results are promising and suggest that A-101 may have the potential to address an unmet medical need and an investigator on multiple A-101 clinical trials. While cryotherapy is the most commonly used treatment for the removal of SK lesions, it is painful for patients and sometimes results in permanent hypopigmentation. A well-tolerated, FDA-approved, non-invasive treatment option for SK would be a welcome advance for patients and physicians.

Similar Private Companies By Industry

Company Name Region
Cephalon, Inc. United States
Pathway Therapeutics Ltd. United States
ACER/EXCEL, Inc. United States
Vitamin Science Inc. United States
Zaina Pharma, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 30, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aclaris Therapeutics, Inc., please visit www.aclaristx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.